Vifor Pharma

12 PBAC submissions on file, active 2013–2023. 83% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Patiromer
  Endocrinology · Recommended with restriction · 2023—
• Difelikefalin
  Nephrology · Recommended with restriction · 2023—
• Ferric carboxymaltose
  Other · Recommended · 2018—
• Ulipristal acetate
  Women's health · Noted · 2017—
• Avacopan
  Immunology · Not recommended · 2024—
• Sucroferric oxyhydroxide
  Endocrinology · Noted · 2015—

Therapy area mix

Activity by year

2013 (1) · 2014 (1) · 2016 (1) · 2017 (1) · 2018 (1) · 2019 (1) · 2020 (1) · 2022 (1) · 2023 (4)

Rejection patterns

Across 2 Not recommended decisions on file.

• 1×unclear clinical criteria and eligibility definition for hyperkalaemia requiring pharmacological intervention
• 1×insufficient justification of placebo comparator versus standard alternatives (intermittent use of polystyrene resins
• 1×dietary modification)
• 1×enriched trial population likely overestimating efficacy in broader population
• 1×uncertain clinical relevance and long-term impact of serum potassium reduction